As previously reported, BofA analyst Jason Gerberry initiated coverage of Arrowhead with a Buy rating and $29 price target. Arrowhead’s Phase 3 drugs, plozasiran and fazirsiran, anchor the firm’s valuation, being valued at $23 per share in the firm’s analysis, the analyst tells investors. The firm sees the late-stage drugs having the potential for about $2.8B in peak sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARWR:
- Biotech Alert: Searches spiking for these stocks today
- Arrowhead reports FY23 EPS ($1.92), consensus ($1.55)
- Arrowhead files for clearance to begin study of ARO-DM1 for DM1 treatment
- ARWR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call